Empagliflozin patent expiry uk?

Q: Empagliflozin patent expiry uk?

Empagliflozin (Jardiance) – UK Patent Landscape Patent (UK) Title / Scope Filing / Grant Date Expiry Date Notes WO2008071793 / GB 2008/014353 “Use of empagliflozin for the treatment of type 2 diabetes” 7 July 2008 (priority: 7 July 2007) 7 July 2028 This is the core “use‑in‑treatment” patent that protects the drug’s indication for diabetes. WO2007085629 / GB 2007/017993 “SGLT2 inhibitors” – broader class claim that includes empagliflozin 30 August 2007 (priority: 30 August 2006) 30 August 2030 This class patent can extend exclusivity for other SGLT2 molecules. WO20100179753 / GB 2010/009378 “Use of empagliflozin in the treatment of type 2 diabetes in combination with other antidiabetic agents” 7 January 2010 (priority: 7 January 2009) 7 January 2030 Combination‑product protection that can delay generic entry for combination regimens. Bottom line: The earliest UK‑registered patent that covers the active ingredient itself (WO2008071793/GB 2008/014353) will expire on 7 July 2028 . A handful of secondary or class patents run until 2030, but they are usually less critical for generic manufacturing once the core patent has expired. What does this mean for generic access? Item Period Impact UK Data Exclusivity 12 years from

Question

Accepted Answer

Empagliflozin (Jardiance) – UK Patent Landscape

Patent (UK)	Title / Scope	Filing / Grant Date	Expiry Date	Notes
WO2008071793 / GB 2008/014353	“Use of empagliflozin for the treatment of type 2 diabetes”	7 July 2008 (priority: 7 July 2007)	7 July 2028	This is the core “use‑in‑treatment” patent that protects the drug’s indication for diabetes.
WO2007085629 / GB 2007/017993	“SGLT2 inhibitors” – broader class claim that includes empagliflozin	30 August 2007 (priority: 30 August 2006)	30 August 2030	This class patent can extend exclusivity for other SGLT2 molecules.
WO20100179753 / GB 2010/009378	“Use of empagliflozin in the treatment of type 2 diabetes in combination with other antidiabetic agents”	7 January 2010 (priority: 7 January 2009)	7 January 2030	Combination‑product protection that can delay generic entry for combination regimens.

Bottom line:
The earliest UK‑registered patent that covers the active ingredient itself (WO2008071793/GB 2008/014353) will expire on 7 July 2028. A handful of secondary or class patents run until 2030, but they are usually less critical for generic manufacturing once the core patent has expired.

What does this mean for generic access?

Item	Period	Impact
UK Data Exclusivity	12 years from

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Empagliflozin patent expiry uk?

What does this mean for generic access?